Please provide your email address to receive an email when new articles are posted on . CD19 CAR T-cell therapy controlled lupus, idiopathic inflammatory myositis and systemic sclerosis in 15 patients ...

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial This phase II trial enrolled 225 evaluable ...

The US Food and Drug Administration (FDA) has approved obecabtagene autoleucel, or obe-cel (AUTO1, Autolus Therapeutics) for the treatment of relapsed or refractory adult B-cell acute lymphoblastic ...

“CD19-directed chimeric antigen receptor (CAR)-modified T-cell therapy represents a new paradigm for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), however, ...

Blinatumomab is a bispecific CD19-directed CD3 T-cell engager. The Food and Drug Administration (FDA) has approved Blincyto ® (blinatumomab) for the treatment of adult and pediatric patients 1 month ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Most though not ...

Credit: Getty Images. CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell therapy. The Food and Drug Administration (FDA) has granted Fast Track designation to CABA-201 for the treatment of ...

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...